162 related articles for article (PubMed ID: 34636513)
1. Development of a Tape-Stripping Liquid Chromatography-Mass Spectrometry Method for Evaluating Skin Deposition of Topical Tazarotene.
Draelos ZD; Draelos MM
J Drugs Dermatol; 2021 Oct; 20(10):1105-1111. PubMed ID: 34636513
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
[TBL] [Abstract][Full Text] [Related]
3. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream.
Draelos Z; Tanghetti E; Werschler W; Kircik L; Angel A; Lagmay E; Guenin E
J Drugs Dermatol; 2022 Mar; 21(3):250-257. PubMed ID: 35254756
[TBL] [Abstract][Full Text] [Related]
5. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
6. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
Tanghetti EA; Werschler WP; Lain E; Guenin E; Harris S; Loncaric A; Pillai R
J Drugs Dermatol; 2020 Mar; 19(3):272-279. PubMed ID: 32549090
[TBL] [Abstract][Full Text] [Related]
7. Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.
Bhatia N; Weiss JS; Sadick N; Cook-Bolden FE; Tyring SK; Guenin E; Loncaric A; Harris S
J Drugs Dermatol; 2020 Jul; 19(7):727-734. PubMed ID: 32726105
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
[TBL] [Abstract][Full Text] [Related]
9. Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex.
Kircik LH; Gold LS; Beer K; Tan J; Baldwin H; Guenin E; Kang R; Varughese J
J Drugs Dermatol; 2020 Aug; 19(8):777-783. PubMed ID: 32845584
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of tazarotene, clindamycin phosphate and their active metabolites in Bama mini-pig skin by LC-MS/MS: Application to the development of a tazarotene/clindamycin phosphate cream.
Lu YT; Hu ZL; Shao FX; Song M; Hang TJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122455. PubMed ID: 33360677
[TBL] [Abstract][Full Text] [Related]
11. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.
Green LJ; Del Rosso JQ; Tanghetti EA; Guenin E
J Drugs Dermatol; 2021 Jun; 20(6):608-615. PubMed ID: 34076400
[TBL] [Abstract][Full Text] [Related]
12. Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.
Stein Gold L; Kircik L; Baldwin H; Callender V; Tanghetti E; Del Rosso J; Zeichner J; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Jun; 21(6):587-595. PubMed ID: 35674760
[TBL] [Abstract][Full Text] [Related]
13. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.
Kircik LH; Green L; Guenin E; Khalid W; Alexander B
J Dermatolog Treat; 2022 Jun; 33(4):2241-2249. PubMed ID: 34459694
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin.
Yu Z; Sefton J; Lew-Kaya D; Walker P; Yu D; Tang-Liu DD
Clin Pharmacokinet; 2003; 42(10):921-9. PubMed ID: 12885265
[TBL] [Abstract][Full Text] [Related]
15. Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.
Kircik LH; Lain E; Gold M; Katz B; Baldwin H; Guenin E; Loncaric A; Pillai R
J Drugs Dermatol; 2020 Nov; 19(11):1086-1092. PubMed ID: 33196747
[TBL] [Abstract][Full Text] [Related]
16. New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
Eichenfield LF; Tanghetti EA; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jun; 19(6):602-610. PubMed ID: 32574011
[TBL] [Abstract][Full Text] [Related]
17. Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.
Tanghetti EA; Zeichner JA; Gold M; Sadick N; Cook-Bolden FE; Kircik LH; Stein Gold L; Weiss J; Tyring SK; Del Rosso JQ; Guenin E
J Dermatolog Treat; 2023 Dec; 34(1):2147391. PubMed ID: 36382987
[TBL] [Abstract][Full Text] [Related]
18. Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies.
Draelos ZD
J Dermatolog Treat; 2023 Dec; 34(1):2166346. PubMed ID: 36622889
[TBL] [Abstract][Full Text] [Related]
19. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II
Baldwin HE; Green LJ; Kircik L; Guenin EP; Forest AL; Pillai R
J Clin Aesthet Dermatol; 2021 Apr; 14(4):E53-E60. PubMed ID: 34055190
[No Abstract] [Full Text] [Related]
20. Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream.
Draelos Z; Tanghetti E; Guenin E
J Drugs Dermatol; 2022 Aug; 21(8):875-880. PubMed ID: 35946981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]